Genelux (GNLX) Preferred Shares (2022 - 2023)

Genelux (GNLX) posted Preferred Shares of $10.0 million for Q2 2023, down 66.59% on a QoQ basis from $29.9 million in Q1 2023.

Analysis

Genelux (GNLX) Preferred Shares (2022 - 2023) Analysis & Trends

Genelux has reported Preferred Shares for 2 years, with the latest figure at $10.0 million in Q2 2023.

On a quarterly basis, Preferred Shares changed N/A year-over-year to $10.0 million in Q2 2023; TTM through Jun 2023 was $10.0 million, a N/A change from a year earlier, with the FY2022 full-year figure at $29.9 million, changed N/A from the prior year.
Preferred Shares was $10.0 million for Q2 2023 at Genelux, down from $29.9 million in the prior quarter.
The five-year high for Preferred Shares was $29.9 million in Q1 2023, with the low at $22000.0 in Q4 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Preferred Shares (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	-
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	-
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	-
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	-
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	-
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	-
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-
10	Genelux	108.17 Mn	108.17 Mn	-	-

Historic Data

Download Data